Olivia Nampewo
Overview
Explore the profile of Olivia Nampewo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
18
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wu L, Ssebuliba T, Muwonge T, Bambia F, Stein G, Nampewo O, et al.
J Acquir Immune Defic Syndr
. 2024 Dec;
98(4):326-333.
PMID: 39630076
Background: Despite high oral pre-exposure prophylaxis (PrEP) uptake among young heterosexual cisgender women, early discontinuation is frequent. It is unclear whether this aligns with potential HIV exposure. Methods: Young women...
2.
Mujugira A, Karungi B, Nakyanzi A, Bagaya M, Nsubuga R, Sebuliba T, et al.
J Acquir Immune Defic Syndr
. 2024 Sep;
97(2):125-132.
PMID: 39250646
Background: Peer-delivered HIV self-testing (HIVST) and sexually transmitted infection self-sampling (STISS) may promote adherence to oral pre-exposure prophylaxis (PrEP), but no studies have analyzed this approach among transgender women (TGW)...
3.
Mujugira A, Nakyanzi A, Bagaya M, Mugisha J, Kamusiime B, Nalumansi A, et al.
AIDS Behav
. 2024 Sep;
29(1):133-142.
PMID: 39222182
Tenofovir alafenamide fumarate (F/TAF) pre-exposure prophylaxis (PrEP) is understudied in sub-Saharan Africa. The Tandika PrEP study was a randomized trial that evaluated same-day F/TAF initiation, the impact of drug-level feedback...
4.
Zewdie K, Muwonge T, Ssebuliba T, Bambia F, Nampewo O, Stein G, et al.
AIDS
. 2024 Aug;
38(14):1965-1971.
PMID: 39088310
Objectives: We evaluated a recently developed and validated point-of-care urine tenofovir (POC TFV) test to determine whether its use improves the accuracy of self-reported adherence to preexposure prophylaxis (PrEP) and...
5.
Mujugira A, Karungi B, Mugisha J, Nakyanzi A, Nampewo O, Naddunga F, et al.
J Int AIDS Soc
. 2024 May;
27(5):e26255.
PMID: 38695107
Introduction: Adherence counselling with point-of-care (POC) drug-level feedback using a novel tenofovir assay may support pre-exposure prophylaxis (PrEP) adherence; however, perceptions of urine testing and its impact on adherence are...
6.
Mujugira A, Karungi B, Mugisha J, Nakyanzi A, Bagaya M, Kamusiime B, et al.
J Int AIDS Soc
. 2023 Dec;
26(12):e26201.
PMID: 38147031
Introduction: Peer delivery is a client-centred approach that could maximize the coverage and impact of HIV services for transgender women (TGW). We conducted qualitative interviews to examine how peer-delivered HIV...
7.
Zia Y, Nambala L, Stalter R, Muwonge T, Ssebuliba T, Nakyanzi A, et al.
AIDS Care
. 2023 Mar;
35(9):1365-1374.
PMID: 36892945
Depression is a common cause of morbidity globally and can impact adherence to medications, posing challenges to medication-based HIV prevention. The objectives of this work are to describe the frequency...
8.
Velloza J, Mujugira A, Muwonge T, Boyer J, Nampewo O, Badaru J, et al.
AIDS Behav
. 2022 Jul;
27(1):279-289.
PMID: 35776250
Low perceived HIV risk is a barrier to effective pre-exposure prophylaxis (PrEP) use among African adolescent girls and young women (AGYW). Single-item risk perception measures are stigmatizing and alienating to...
9.
Mujugira A, Nakyanzi A, Nabaggala M, Muwonge T, Ssebuliba T, Bagaya M, et al.
J Acquir Immune Defic Syndr
. 2021 Dec;
89(4):381-389.
PMID: 34954718
Background: HIV self-testing (HIVST) and pre-exposure prophylaxis (PrEP) are complementary tools that could empower sex workers to control their HIV protection, but few studies have jointly evaluated PrEP and HIVST...